LON:NFX

Nuformix (NFX) Share Forecast, Price & News

GBX 0.86

+0.05 (+6.17%)

(As of 05/27/2022 12:00 AM ET)

Add

Compare

Today's Range: 0.76
▼
0.95
50-Day Range: 0.78
▼
1.05
52-Week Range: 0.75
▼
2.40

Volume: 4.43 million shs
Average Volume: 4.11 million shs
Market Capitalization: £6.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive NFX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuformix and its competitors with MarketBeat's FREE daily newsletter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. Its lead programs include NXP001, which is in Phase 1-ready stage for oncology supportive care; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. The company is also developing NXP004, which is in the research Phase for treating oncology. It also has an option agreement with Oxilio Ltd. for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

April 12, 2022 | proactiveinvestors.com

Nuformix will receive a gross £1.32mln from second tranche of Lanstead funding agreement

April 5, 2022 | marketwatch.com

Nuformix Shareholder Raises Stake to 16.6%

December 14, 2021 | marketwatch.com

Nuformix Investor Subscription to Raise GBP1.7 Mln for Product Development

December 14, 2021 | marketwatch.com

Nuformix 1H Loss Narrowed Slightly on Lower Costs

November 25, 2021 | marketwatch.com

Nuformix Shares Rise on Positive Trial Studies

November 12, 2021 | marketwatch.com

Nuformix Files New Patent Application for Cancer Treatment

November 9, 2021 | lse.co.uk

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

October 21, 2021 | lse.co.uk

Chill Brands Share Chat

September 14, 2021 | lse.co.uk

LONDON BRIEFING: AB Foods says Primark sales growth hit by 'pingdemic'

September 13, 2021 | marketwatch.com

Nuformix Shares Rise on Global Agreement for Cancer-Drug License

July 23, 2021 | proactiveinvestors.com

No knee jerk reaction from Nuformix over CEO resignation

July 22, 2021 | lse.co.uk

EXECUTIVE CHANGES: Nuformix responds to "frustration" as CEO departs

July 21, 2021 | lse.co.uk

Nuformix Chief Executive Brindley to step down in six months time

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:NFX
Previous Symbol: LON:LVRT
CUSIP: N/A
CIK: N/A
Web: www.levrett.com
Phone: 44 1223 423 667
Fax: N/A
Employees: 5
Year Founded: N/A

Sales & Book Value

Annual Sales: £50 thousand
Price / Sales: 122.00
Cash Flow: GBX 0.20 per share
Price / Cash Flow: 4.30
Book Value: GBX 0.90 per share
Price / Book: 0.96

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 1.17
Current Ratio: 7.56
Quick Ratio: 7.56

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 709,308,992
Free Float: N/A
Market Cap: £6.10 million
Optionable: Optionable

Company Calendar

Last Earnings: 7/22/2020
Today: 5/28/2022
Next Earnings (Estimated): 7/20/2022

MarketRank^™

Overall MarketRank^™

1.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Nuformix.

4.4 Community Rank

Outperform Votes
Nuformix has received 68 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Nuformix has received 34 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Nuformix has received 66.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Nuformix and other stocks. Vote “Outperform” if you believe NFX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NFX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Nuformix does not currently pay a dividend.
Dividend Growth
Nuformix does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuformix insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Nuformix is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nuformix is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nuformix has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Nuformix (LON:NFX) Frequently Asked Questions

When is Nuformix's next earnings date?: Nuformix is scheduled to release its next quarterly earnings announcement on Wednesday, July 20th 2022.
View our earnings forecast for Nuformix.
How were Nuformix's earnings last quarter?: Nuformix plc (LON:NFX) posted its earnings results on Wednesday, July, 22nd. The company reported ($0.16) EPS for the quarter.
View Nuformix's earnings history.
Who are Nuformix's key executives?: Nuformix's management team includes the following people:
Dr. Joanne M. Holland, Consultant (Age 47, Pay $97k)
Dr. Alastair James Riddell M.D., M.Sc., MBChB, MFPM, MRCGP, MSc, Ph.D., Exec. Chairman (Age 73)
Mr. Benjamin Harber, Company Sec.
Who are some of Nuformix's key competitors?: Some companies that are related to Nuformix include Liberty Biopharma (LTY), OptiBiotix Health (OPTI), ReNeuron Group (RENE), AorTech International (AOR), Hemostemix (HEM), NetScientific (NSCI), Oxford BioDynamics (OBD), Ensysce Biosciences (ENSC), IXICO (IXI), Bioasis Technologies (BTI), ImmuPharma (IMM), ValiRx (VAL), Quest PharmaTech (QPT), Hemogenyx Pharmaceuticals (HEMO) and Crescita Therapeutics (CTX).
View all of NFX's competitors.
What other stocks do shareholders of Nuformix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nuformix investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Inovio Pharmaceuticals (INO), Senseonics (SENS), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Acasti Pharma (ACST), Adamis Pharmaceuticals (ADMP) and Aldeyra Therapeutics (ALDX).
What is Nuformix's stock symbol?: Nuformix trades on the London Stock Exchange (LON) under the ticker symbol "NFX."
How do I buy shares of Nuformix?: Shares of NFX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Nuformix's stock price today?: One share of NFX stock can currently be purchased for approximately GBX 0.86.
How much money does Nuformix make?: Nuformix has a market capitalization of £6.10 million and generates £50 thousand in revenue each year.
How many employees does Nuformix have?: Nuformix employs 5 workers across the globe.
What is Nuformix's official website?: The official website for Nuformix is www.levrett.com.
How can I contact Nuformix?: Nuformix's mailing address is Ste 31 Second Fl, 107 Cheapside, LONDON, EC2V 6DN, United Kingdom. The company can be reached via phone at 44 1223 423 667.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.